首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients: 8-year follow-up of CARE-MS II (Topaz Study)
【24h】

Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients: 8-year follow-up of CARE-MS II (Topaz Study)

机译:Alemtuzumab在RRMS患者中提高了临床和MRI疾病活动结果,包括脑体积损失的放缓:Care-MS II(Topaz研究)的8年后续行动

获取原文
获取原文并翻译 | 示例
       

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号